Ascendis Pharma announced that its once‑weekly growth‑promoting therapy, YUVIWEL® (navepegritide), received accelerated approval from the U.S. Food & Drug Administration on February 27 2026, and that the drug is now commercially available in the United States. The announcement also confirmed that YUVIWEL® has been granted orphan drug exclusivity, giving the company a seven‑year period of marketing exclusivity for treating children aged two years and older with achondroplasia.
YUVIWEL® is indicated for children 2 years and older with achondroplasia who have open epiphyses, and it delivers a once‑weekly dose thanks to Ascendis’ proprietary TransCon technology. The once‑weekly regimen contrasts with the daily injections required for the only other approved therapy, Vosoritide (Voxzogo). Global estimates place the prevalence of achondroplasia at roughly 150,000 individuals, a figure that is lower than the 250,000 cited in the original article.
The launch marks the third FDA‑approved TransCon product for Ascendis, following SKYTROFA® and YORVIPATH®. It strengthens the company’s rare‑disease portfolio and supports its Vision 2030 growth targets. In addition, the FDA’s approval granted a rare‑pediatric disease priority review voucher, which can be used to expedite the review of a future drug application.
Analysts have responded with a moderate‑buy consensus and an average price target of $289.89. The approval is viewed as a potential market disruptor, as YUVIWEL® offers a more convenient dosing schedule that could broaden patient adherence and market share in the achondroplasia segment.
Jan Mikkelsen, President and CEO, said, “We’re excited to see the FDA grant orphan drug exclusivity for Yuviwel, acknowledging it as a highly differentiated treatment option. We have now delivered and commercialized our third FDA‑approved TransCon product in a row, and remain on track to fulfill our objective of being the leader in Growth Disorders.” A mother of a child with achondroplasia, Brandi, added, “Our daughter has gained new independence and confidence with her growth, following treatment with YUVIWEL in a clinical trial.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.